{"id":"W4413111668","doi":"10.1016/j.esmoop.2025.105544","title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Eisai; Daiichi-Sankyo; Arena Pharmaceuticals; G1 Therapeutics; Incyte; Sanofi; Exelixis; Merck KGaA; Gilead Sciences; Ipsen; Mirati Therapeutics; Clovis Oncology; EUSA Pharma; Seagen; Roche; Pfizer; Eli Lilly and Company; AstraZeneca; National Cancer Institute; Accuray","keywords":"Medicine; Pembrolizumab; Internal medicine; Carboplatin; Gemcitabine; Oncology; Metastatic Urothelial Carcinoma; Clinical endpoint; Chemotherapy; Phases of clinical research; Population; Cisplatin; Cancer; Gastroenterology; Bladder cancer; Randomized controlled trial; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004005995,0.0003260536,0.0009334638,0.0003035303,0.00004685894,0.00004026121,0.0003252337,0.00004342914,0.0001976703],"category_scores_gemma":[0.00008749377,0.000242179,0.00006102707,0.001500782,0.00005607065,0.0002485057,0.00008265099,0.0001293802,0.000007377511],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007203572,"about_ca_system_score_gemma":0.001716689,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01224008,"about_ca_topic_score_gemma":0.02421559,"domain_scores_codex":[0.9977903,0.0002637492,0.0006413931,0.0005301793,0.0004303183,0.0003440795],"domain_scores_gemma":[0.9989562,0.00007732159,0.0001598709,0.0004799369,0.0002015521,0.0001251225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6861902,0.0252812,0.2062248,0.0003240409,0.00245559,0.001137662,0.01222406,0.0009218,0.0009498282,0.0001649463,0.0001986261,0.06392731],"study_design_scores_gemma":[0.6395378,0.03746598,0.2988008,0.001033835,0.001539397,0.00001427861,0.006724923,0.0009014869,0.01326002,0.0001141981,0.000108235,0.0004990889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990616,0.0001327353,0.0001753025,0.0002185203,0.00009203909,0.007193859,0.0000340836,0.00002692955,0.001510493],"genre_scores_gemma":[0.9980612,0.00002438111,0.0004042502,0.000261565,0.000009715417,0.0008102946,0.00005400724,0.00002917241,0.0003453656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09257601,"threshold_uncertainty_score":0.9943375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06668643470950594,"score_gpt":0.426261484299137,"score_spread":0.359575049589631,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}